Literature DB >> 2831519

High affinity binding of VIP to human lung cancer cell lines.

M M Shaffer1, D N Carney, L Y Korman, G S Lebovic, T W Moody.   

Abstract

The binding of 125I-VIP to human lung cancer cell lines was investigated. Radiolabeled VIP bound to adenocarcinoma, squamous cell carcinoma, large cell carcinoma and small cell lung cancer (SCLC) cell lines. As SCLC cell line NCI-N592 bound radiolabeled VIP well, its binding was further characterized. 125I-VIP bound to membranes in a specific and time dependent manner. 125I-VIP bound with high (Kd = 0.8 nM) and moderate affinity (Kd = 66 nM) to two classes of sites. Pharmacology studies indicated that the order of peptide potency was VIP much greater than PHI greater than secretin greater than VIP10-28. Because VIP receptors are present on human lung cancer cells, VIP may function as a regulatory peptide in lung cancer.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2831519     DOI： 10.1016/0196-9781(87)90143-4

Source DB:  PubMed          Journal:  Peptides        ISSN： 0196-9781            Impact factor:   3.750


  9 in total

1.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

Review 2.  Regulation of VIP gene expression in general. Human lung cancer cells in particular.

Authors:  A Davidson; T W Moody; I Gozes
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

Review 3.  VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment.

Authors:  J M Muller; V Lelievre; L Becq-Giraudon; A C Meunier
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

4.  Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.

Authors:  K Maruno; A Absood; S I Said
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

5.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

6.  Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects.

Authors:  G Bepler; M Rotsch; G Jaques; M Haeder; J Heymanns; G Hartogh; P Kiefer; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

7.  VPAC1 receptors and lung cancer.

Authors:  T W Moody; J Walters; M Casibang; F Zia; Y Gozes
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

8.  A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.

Authors:  A Sharma; J Walters; Y Gozes; M Fridkin; D Brenneman; I Gozes; T W Moody
Journal:  J Mol Neurosci       Date:  2001-12       Impact factor: 3.444

9.  Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells.

Authors:  F Zia; M Fagarasan; K Bitar; D H Coy; J R Pisegna; S A Wank; T W Moody
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.